HNWAG
KDNY

High Net Worth Advisory Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

High Net Worth Advisory Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$26.2K – 618
2022
Q4 		$26.2K Hold
1,000
– – 0.01% 401
2022
Q3 		$20K Hold
1,000
– – 0.01% 454
2022
Q2 		$17K Hold
1,000
– – 0.01% 479
2022
Q1 		$16K Hold
1,000
– – 0.01% 481
2021
Q4 		$16K Buy
+1,000
New +$14.2K 0.01% 499

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

High Net Worth Advisory Group's KDNY Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 1,000 shares — an estimated $26.2K sold.

High Net Worth Advisory Group first reported a position in KDNY in Q4 2021 and held it in 5 quarters. The position peaked at $26.2K in Q4 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $26.2K.
  • High Net Worth Advisory Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
  • High Net Worth Advisory Group's Chinook Therapeutics, Inc. Common Stock position peaked at $26.2K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.